title: Suite PET/CT neuroimaging for the diagnosis of Parkinson's disease: statistical parametric mapping analysis.
abstract: OBJECTIVE
  The aim of this study was to investigate the topographical distribution of dopamine transporter (DAT), dopamine D2 receptor, and glucose metabolism in Parkinson's disease (PD) using PET/computed tomography (CT) scanning and statistical parametric mapping (SPM) analysis.
  
  
  METHODS
  Seventy-four patients (58 PD patients and 16 normal controls) underwent DAT, D2 receptor, and glucose brain PET/CT scans using C-methyl-N-2-β-carbomethoxy-3-β-(4-fluorophenyl) tropane (C-β-CFT), C-raclopride (C-RAC), and fluorine-18-fluorodeoxyglucose (F-FDG) radiotracers for the respective scans. All three PET/CT procedures were performed in each participant. The uptake patterns were analyzed using SPM software.
  
  
  RESULTS
  Striatal DAT binding was lower in PD patients than in controls, whereas D2 receptor binding did not differ between PD patients and controls. D2 receptor binding was increased in the putamen in only the 12 drug-naive patients. Glucose uptake was also slightly lower in the cingulate gyrus of PD patients than in the controls.
  
  
  CONCLUSIONS
  Suite PET/CT scans using the ligands C-β-CFT, C-RAC, and F-FDG PET/CT are valuable for diagnosing PD. SPM-based analysis of static PET/CT scan data is potentially of great clinical use.
authors.affiliation: Departments of aNuclear Medicine bGeriatric Neurology cHematology, PLA General Hospital, Beijing dDepartment of Nuclear Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
authors.forename: Ruimin
authors.initials: R
authors.lastname: Wang
authors.forename: Baixuan
authors.initials: B
authors.lastname: Xu
authors.forename: Zhe
authors.initials: Z
authors.lastname: Guo
authors.forename: Tong
authors.initials: T
authors.lastname: Chen
authors.forename: Jinming
authors.initials: J
authors.lastname: Zhang
authors.forename: Yingmao
authors.initials: Y
authors.lastname: Chen
authors.forename: Haiyan
authors.initials: H
authors.lastname: Zhu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism; D001931:Brain Mapping / Q000379:methods / Q000706:statistics & numerical data; D016022:Case-Control Studies; D003042:Cocaine / Q000031:analogs & derivatives; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism; D005260:Female; D019788:Fluorodeoxyglucose F18; D059907:Functional Neuroimaging / Q000379:methods* / Q000706:statistics & numerical data; D005947:Glucose / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D057054:Molecular Imaging / Q000379:methods / Q000706:statistics & numerical data; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000378:metabolism; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods* / Q000706:statistics & numerical data; D020891:Raclopride; D019275:Radiopharmaceuticals; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D055815:Young Adult
chemical_list: C581293:DRD2 protein, human; D050483:Dopamine Plasma Membrane Transport Proteins; D019275:Radiopharmaceuticals; D017448:Receptors, Dopamine D2; D019788:Fluorodeoxyglucose F18; D020891:Raclopride; C021279:(1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester; D003042:Cocaine; D005947:Glucose